TAC Security Acquires CyberScope Europe-Based Web3 Security Firm
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- TAC Security, a NSE Listed (NSE:TAC) global leader in risk-based vulnerability management, has announced its acquisition of CyberScope, a premier Web3 security firm specializing in smart contract audits, crypto security audit and blockchain vulnerability assessments. This strategic acquisition solidifies TAC Security's dominance in Web3 security, positioning the company as the undisputed leader in securing blockchain ecosystems.
CyberScope, known for its successful track record of 2,780 audits and $134 billion in secured assets, has become an industry pioneer in Web3 security. This acquisition accelerates TAC Security's global expansion, adding smart contract audit to its vulnerability management portfolio and extending its European footprint. With over 6,000 clients worldwide and a target of 10,000 by 2026, the combined company will offer integrated vulnerability management solutions across Web3 and cybersecurity markets, providing unmatched protection for blockchain-based applications.
As part of the deal, CyberScope's suite of security tools will be seamlessly integrated into TAC Security's platform. Additionally, CyberScope's smart contract audit services are now integrated into TAC Security's ESOF, making it the first vulnerability management company globally to offer Web3 security and smart contract audits.
Trishneet Arora, Founder and CEO of TAC Security, commented, ' The acquisition of CyberScope propels us toward becoming the world's largest vulnerability management company. With their expertise in smart contract audits and a global client base, we are on track to achieve our goal of 10,000 clients by 2026. As Web3 security becomes increasingly critical, this acquisition strengthens our position as a leader in blockchain security.'
This acquisition is a major milestone for TAC Security's growth strategy and reinforces its commitment to offering comprehensive cybersecurity solutions to its expanding global client base.
Media Contact–
TAC Security Corporate Communications Team
TAC Security, is a publicly listed cybersecurity company that made headlines with its oversubscribed IPO worth $1 billion. TAC Security's flagship product, ESOF (Enterprise Security in One Framework), excels in cyber scoring, cyber risk quantification, and leveraging advanced AI for vulnerability assessment and penetration testing.
TAC Security holds prestigious certifications like CREST and ISO 27001 and partners with tech giants for ADA's CASA. Serving a diverse global clientele, TAC Security is committed to innovation and excellence in cyber security for Fortune 500 companies, start-ups, and Governments Globally.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
'Pogback' is trending on ‘X' as Paul Pogba set to join AS Monaco
Footballing master Paul Pogba is back and he is all set to join AS Monaco as the contract has been prepared and the negotiations have been done. By Ravi Kumar Jha Published on June 23, 2025, 08:36 IST Footballing master Paul Pogba is back and he is all set to join AS Monaco as the contract has been prepared and the negotiations have been done. The deal will be done and sealed soon as per Fabrizio Romano. The player who was banned for doping is now getting more than excited to be back on the field. Monaco showed greath enthusiasm in getting this deal over the line as there were few other clubs interested in the midfielder. French midfield maestro Paul Pogba is on the verge of making a sensational return to professional football, with a move to AS Monaco all but confirmed. According to transfer expert Fabrizio Romano, the contract has been prepared, negotiations are complete, and the deal is expected to be signed and sealed soon. Pogba, who was handed a lengthy ban due to a doping violation, has been away from the field since last year. However, the experienced player is now more motivated than ever to make a strong comeback and reignite his career. AS Monaco have shown great enthusiasm in securing Pogba's services despite competition from a few other clubs. The Ligue 1 side is eager to add the World Cup winner's experience and quality to their midfield as they look to strengthen for the upcoming season. With the ban reached it's conclusion, Pogba's return could be one of the most talked-about comebacks in European football. Ahmedabad Plane Crash AS MonacoChampions LeagueFootballJuventusLigue 1MonacoPaul PogbaPogback Ravi kumar jha is an undergraduate student in Bachelor of Arts in Multimedia and Mass Communication. A media enthusiast who has a strong hold on communication and he also has a genuine interest in sports. Ravi is currently working as a journalist at
Business Insider
12 hours ago
- Business Insider
Women are getting wealthier — and they don't invest the same way as men
Women are becoming richer, and they're changing the face of wealth. According to a report by McKinsey published last month, women control about a third of all retail financial assets in the US and the European Union. By 2030, that proportion is expected to rise to between 40% to 45%, wrote Cristina Catania, global co-convener and European lead for the risk and resilience practice, and Jill Zucker, senior partner and co-leader of McKinsey's global growth transformation service line. The report is based on a survey of about 13,000 American and European investors, nearly half of whom were female financial decision makers. It found that between 2018 and 2023, global wealth rose by 43%, but jumped by 51% for women. Women's expanding control of assets is being driven by a combination of factors, including a continuing decline in marriage rates, the ongoing boost in women's average earnings, demographic trends like longer life expectancies, and a broad shift in attitudes about women managing their own finances. Risk doesn't equal reward As women become wealthier through investing, it's becoming clearer that they don't approach it the same way as men. "Women are much more risk-aware," Anna-Sophie Hartvigsen, cofounder of financial education and investment platform Female Invest, told Business Insider. "I would like to call it much more realistic in their own ability to invest." She said women are less likely than men to invest emotionally. "On average, men trade a lot more often than women because they believe they can beat the market or they read something in the news, and they get pumped up or afraid, and then they invest based on that," Hartvigsen said. Female investors, in her view, tend to be more calm, more realistic, and better at assessing risk. However, Katie Geery, an advisor at Rise Private Wealth Management, says being more cautious can also hold women back by leading them to miss out on opportunities to build wealth. "It is important to work with a trusted financial advisor who understands your risk tolerance and can walk you through making well-educated investment decisions based on your long-term goals," she told BI. Returns aren't everything The aims of investing also sometimes differ between men and women. "Women prefer to invest toward achieving specific goals rather than chasing the highest returns," said Avanti Shetye, financial planner at Wealthwyzr. Geery said female investors tend to be more focused on philanthropy and gifting. They often consider their values when buying stock and want their purchases to help make a better impact on the world. "Women often seek financial advisors who are empathetic and take the time to get to know them on a more personal level to gain a deeper understanding of their goals and values," she said. On Female Invest, Hartvigsen said the principles its members care about the most include climate, especially a firm's carbon footprint, and diversity in leadership, in terms of a board having a good gender balance. Start investing early For Shetye, it's important to start investing early. "Women tend to be primary caregivers for children or aging parents and often take unpaid time off," she said. "Not only that, women statistically live longer than men, which implies that women would need to invest as much as they can as early as possible so that their portfolios last them through retirement." Hartvigsen said long-term financial planning is vital: "When you do that, it doesn't matter what happens today." Both agree that this plan should be grounded in expert advice. "Working with a financial planner whose planning process is rooted in financial education can help provide comfort and security to stay consistent even in the roughest of markets," Shetye said. But she also believes that practice is more important than perfection. "You are never going to know everything there is to know about investing," Shetye said. "The key is consistency, and time will do the heavy lifting." Hartvigsen advises her clients to invest monthly on the same day and to diversify their investments. "If you do that, historically, it has been near impossible not to make money in the long run."
The Hill
12 hours ago
- The Hill
Food and Drug Administration staff cuts may hinder US biomedical innovation
President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.
